China approves first commercial brain implant, surpassing Neuralink

China has officially approved its first commercial brain implant, leapfrogging Neuralink in the race to bring mind-controlled technology to patients. The move signals a new front in the geopolitical contest between Beijing’s rapid, state-driven innovation and Washington’s more cautious regulatory framework.

What once belonged to the realm of science fiction is now a regulated medical reality. Earlier this year, China’s National Medical Products Administration granted commercial approval to NEO, a coin-sized brain-computer interface (BCI) developed by Shanghai-based NeuraMatrix in collaboration with Tsinghua University. This marks the first time any national regulator has cleared an invasive BCI device for commercial use, specifically for patients with spinal cord injuries.

The NEO implant is inserted during a 90-minute procedure, with eight sensors placed on the dura mater, the protective membrane covering the brain. Unlike Neuralink’s approach, which threads electrodes directly into brain tissue, NEO rests on top of the membrane. The system decodes neural signals in real time, allowing patients to control a pneumatic glove with their thoughts. Simple actions like grasping objects or drinking water become possible for those who lost hand movement.

This approval follows the same state-backed playbook that propelled China’s electric vehicle industry to global dominance. Beijing has designated BCI as one of six strategic future industries, set a national goal of world leadership in brain technology by 2030, and removed regulatory barriers to accelerate clinical trials. The result is a wave of Chinese BCI startups backed by state funding and fast-tracked through a regulatory process that took years elsewhere. The approach prioritizes speed and scale over the more cautious, phased approval pathways required by the U. S. Food and Drug Administration.

Across the Pacific, Neuralink has implanted its N1 device in at least 21 patients under research protocols. Its first patient, Noland Arbaugh, demonstrated the ability to play chess, browse the web, and control a cursor with thought alone. But Neuralink does not yet have commercial approval. The company plans to ramp up to high-volume production and near-fully automated surgery in 2026, but FDA clearance for commercial sale is realistically years away.

Other U. S. competitors are taking different routes. Synchron, which inserts its Stentrode device through the jugular vein rather than open brain surgery, holds the first FDA investigational device exemption for a permanently implanted BCI and is using a $200 million Series D to fund a pivotal trial this year. Precision Neuroscience cleared the 510(k) pathway in April 2025 and partnered with Medtronic to embed its technology into existing neurosurgery systems. Despite these advances, no BCI is commercially available in the United States. All current implants are performed under research protocols or expanded access programs.

The technology has moved well beyond laboratory demonstrations. Patients with implanted BCIs have browsed the internet, moved robotic arms, and transcribed thoughts into text. These advances are driven by two converging trends: better hardware that can read more brain signals with less surgical risk, and AI models that decode those signals faster and more accurately. As both improve, the range of actions a BCI can translate expands.

At its best, BCI technology restores autonomy for millions of people who have lost it to paralysis, blindness, hearing loss, or other conditions. The medical case is clear and the need is enormous. The harder questions begin when the technology moves beyond restoration. Some researchers believe BCIs could lead to new forms of AI by modeling how the brain processes information. Others see a path to augmented human abilities, enhancing memory, accelerating learning, or enabling direct brain-to-brain communication.

Those possibilities raise questions that regulators are not yet equipped to answer. Who owns the data a brain implant collects? Can a government compel access to neural signals? What happens when the line between treating a disability and enhancing a healthy brain becomes commercial rather than medical? China’s approval of NEO is a milestone for patients who need the technology now. It is also the starting gun for a global competition in which the rules have not yet been written.